{"denoms":[{"counts":[{"groupId":"BG000","value":"276"},{"groupId":"BG001","value":"276"},{"groupId":"BG002","value":"552"}],"units":"Participants"}],"groups":[{"description":"Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV on Days 1, 2, 3 for 6 cycles.","id":"BG000","title":"Fludarabine+Cyclophosphamide (FC)"},{"description":"Rituximab and FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: rituximab 375 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 2, 3, 4; cyclophosphamide 250 mg/m² IV on Days 2, 3, 4. Cycles 2-6: rituximab 500 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 1, 2, 3; cyclophosphamide 250 mg/m² IV on Days 1, 2, 3.","id":"BG001","title":"Fludarabine+Cyclophosphamide+Rituximab (FCR)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.11","value":"61.3"},{"groupId":"BG001","spread":"9.17","value":"62.1"},{"groupId":"BG002","spread":"9.14","value":"61.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"184"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"181"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"368"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}